- Home
- LIVN
LIVN
LivaNova PLC
as 08-28-2025 3:33pm EST
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
| Founded: | 1987 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.1B | IPO Year: | 1993 |
| Target Price: | $59.71 | AVG Volume (30 days): | 774.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $32.48 - $57.35 | Next Earning Date: | 08-06-2025 |
| Revenue: | $1,309,329,000 | Revenue Growth: | 8.23% |
| Revenue Growth (this year): | 11.29% | Revenue Growth (next year): | 6.59% |
Stock Insider Trading Activity of LivaNova PLC (LIVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bianchi Francesco | LIVN | N/A | Aug 25 '25 | Sell | $56.50 | 1,500 | $84,750.00 | 9,028 |
Latest LivaNova PLC News
LIVN Breaking Stock News: Dive into LIVN Ticker-Specific Updates for Smart Investing
Zacks
2 months ago
Are Options Traders Betting on a Big Move in LivaNova Stock?
Argus Research
2 months ago
LIVN: Rating decreased to a SELL
Morningstar Research
3 months ago
Analyst Report: LivaNova PLC
Medical Device Network
3 months ago
LivaNova completes epilepsy treatment study of VNS Therapy
Business Wire
3 months ago
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
Business Wire
3 months ago
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
MT Newswires
3 months ago
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment
Business Wire
3 months ago
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
Compare LIVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LIVN LivaNova PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.